Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc." is generating significant coverage in the Business category, with 13 articles from 13 distinct sources tracked by PULSE so far.
Outlets currently covering the story include BioPharma Dive, FirstWord Pharma, qz.com and Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 88d ago.
Quick answers
Why is "Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc." trending?
Because 13 independent news sources published 13 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (13)
- Biogen adds more immune drugs in $1B buyout of secretive startup RayThera BioPharma Dive · 90d ago
- Biogen snaps up RayThera in $1B immunology deal FirstWord Pharma · 90d ago
- Biogen acquires RayThera in deal worth up to $1 billion qz.com · 90d ago
- Biogen targets immunology growth with $1 billion RayThera deal Reuters · 90d ago
- Biogen Inc. entered into a definitive agreement to acquire RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others for $1 billion. marketscreener.com · 90d ago
- Needham reiterates Buy on Biogen stock after RayThera acquisition Investing.com · 90d ago
- Needham reiterates Buy on Biogen stock after RayThera acquisition By Investing.com Investing.com Canada · 90d ago
- Biogen inks $1B RayThera buyout to bag preclinical immunology assets Fierce Biotech · 90d ago
- BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal Stocktwits · 90d ago
- Biogen Expects to Close Deal in 3Q Moomoo · 90d ago
- Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion GuruFocus · 90d ago
- Biogen makes up to $1B deal for secretive anti-inflammatory biotech Endpoints News · 90d ago
- Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. Biogen · 90d ago
Topics
Related trends
Brent Hits $108 as Saudi Pipeline Shutdown Deepens Supply Fears
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Oil Jumps as Shutdown of Saudi Pipeline Deepens Energy Crisis
1 news sources are covering this World story right now — PULSE is tracking how fast it spreads.
Closure of Critical Saudi Oil Pipeline Puts Iraq Under Pressure
1 news sources are covering this World story right now — PULSE is tracking how fast it spreads.
Chronic type II interferon promotes tumor growth through mitochondrial RNA–induced type I interferon and prostaglandin synthesis
New research reveals how chronic type II interferon can inadvertently promote tumor growth via mitochondrial RNA and prostaglandin synthesis.
Tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species
Recent scientific coverage details how tumor-derived antioxidants suppress immunity by depriving T cells of reactive oxygen species.
New clues suggest how destructive immune cells wreak havoc in the brain
New scientific evidence from AAAS reveals potential mechanisms through which destructive immune cells cause damage within the human brain.